Genome / Exome-Seq, Targeted Seq, RNA-Seq

2023--Closing latest financing round with QiMing Venture Partners

Complete Omics proudly announces its latest financing round's success, significantly backed by Qiming Venture Partners, China's top healthcare VC. This achievement is particularly remarkable given the current economic climate, where securing investment has become increasingly challenging, especially in the healthcare and pharmaceutical sectors. Our team's dedication and resilience have been key in reaching this pivotal moment for our company. Our collaboration with Qiming, known for investing in industry leaders like Xiaomi (1810.HK), Meituan (3690.HK), and Bilibili (BILI), signals strong confidence in our mission and future. This investment propels us into new realms of innovation in clinical proteomics and molecular diagnostics, underscoring our commitment to transforming healthcare. It positions us among influential firms, promising a future of growth and breakthroughs despite the economic slowdown. We're excited for what's ahead and invite our community to join us in this journey towards significant healthcare advancements. Together, we're poised to redefine the landscape of personalized medicine. (Ref. 1, 2).

1. Media Resource: Clinical Proteomics Startup Complete Omics Inc. Successfully Completes Series A Financing, Exclusively Invested by Qiming Venture Partners
2. Media Resource: Bloomberg News: Qiming Venture Partners' Rieschel on China VC Market

2022--Direct Identification and Quantification of Neoantigens from Minute Amount of Clinical Biopsy Sample --- published on Cancers

In recent years, neoantigens are becoming popular cancer therapeutic targets under intensive studies by almost all major oncology pharmaceuticals. However, who are the target patients? Does the patient with a "correct" mutation and a "correct" HLA allele indeed present the "correct" neoantigen? Is this individual's neoantigen copy number high enough for immunotherapy? AI predictions based on NGS genomic information have been proven incapable of answering these questions. Immunopeptidome through mass spectrometry is dominated by disease-irrelevant peptide sequences.  There is no existing way to identify and quantify neoantigens from a minute amount of clinical biopsy sample, such as 50 mg tissue or less. Valid-NEO is developed to fit this demanding clinical need through combining our proprietary multi-omics platforms including NGS-based ultra-rare mutation calling technique, DEEPER-SeqS, and our unique clinical proteomics platform, Complete360^®, with additional hardware innovations (Ref. 1).

1. Publication: Valid-NEO: A Multi-Omics Platform for Neoantigen Detection and Quantification from Limited Clinical Samples.

2022--Identify and Quantify Neoantigens derived from Human endogenous retroviruses (HERVs) --- published on Science Advances

Human endogenous retroviruses (HERVs) represent 8% of the human genome. Working with, ErVaccine Technologies, our scientists identified neoantigens encoded by HERVs across a broad spectrum of cancers, and this finding may help enable next-generation therapeutic vaccines and cellular immunotherapies targeting these so-called “unconventional” tumor antigens (Ref 1). These antigens are shared by different tumor types. They would prove useful as personalized cancer therapeutic targets for a large number of patients. Along the side when we are keep on improving and developing our own disease detection and companion diagnostic pipelines, we are excited to be working with a large number of collaborators to implement our multi-omics platforms in their different clinical and basic research projects.

1. Publication: Identification of shared tumor epitopes from endogenous retroviruses inducing high avidity cytotoxic T cells for cancer immunotherapy.

2021--Therapeutic Neoantigens Encoded by Oncogene K-Ras --- published on Science Immunology

K-Ras is one of the most highly mutated oncogenes in cancers. The neoantigens encoded by K-Ras can be presented by many different types of cancer cells. Here we utilized our multi-omics neoantigen validation pipeline to detect and quantify K-Ras neoantigens from a variety of cancer samples (Ref 1.). We found that the K-Ras as well as several other oncogenes can be presented on cancer cell surface, but at extremely low copy numbers.  We adopted a variety of internal control system to measure their abundance down to <1 copy per cell level. To come up with an actionable strategy, the therapeutic team at JHU developed bispecific antibodies that can target the neoantigens we identified, and deliver dramatic therapeutic effects to mice. These findings are significant in the way that it opens a gate to developing pan-cancer immunotherapeutic agents that can treat a large number of patients sharing cancer hotspot mutations. Identifying such neoantigens is the first step in this campaign and is being accomplished by Complete Omics Inc.

1. Publication: Bispecific antibodies targeting mutant RAS neoantigens.

2021--Direct Quantification of Neoantigens Like Never Before --- published on Science

Genetic changes in human genome are the driving force for all cancers. Different patients have different sets of mutation profiles even for the  patients who all have the same disease. For decades, doctors, cancer researchers, and pharmaceutical companies have been working tirelessly trying to find a way to treat each person's unique disease in a highly personalized way that will reach the maximum treatment efficacy with the lowest side effects. Complete Omics, working with leaders in cancer therapeutics, has developed pipelines based on our multi-omics techniques through which we clearly observe and quantify personalized therapeutic targets encoded by the most frequently mutated tumor suppressor gene TP53. We validated and quantified the TP53 neoantigens on the surfaces of cancers and provided information to healthcare providers to support their decision on if or not to adopt a highly personalized cancer treatment targeting these neoantigens and when to use it (Ref 1). These findings provided the 1st-hand evidence for cancer therapeutics without the uncertainty that comes with predictions.

1. Publication: Targeting a neoantigen derived from a common TP53 mutation.